---
title: "Lendway Inc. Launches Rights Offering to Slash Debt"
description: "Lendway Inc. has launched a rights offering to reduce its debt significantly. The proceeds will be used to settle a sellers’ note at over a 50% discount and pay off other debts, potentially reducing o"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273660225.md"
published_at: "2026-01-26T07:08:05.000Z"
---

# Lendway Inc. Launches Rights Offering to Slash Debt

> Lendway Inc. has launched a rights offering to reduce its debt significantly. The proceeds will be used to settle a sellers’ note at over a 50% discount and pay off other debts, potentially reducing overall debt by up to 40% immediately and 70% by early summer. The company will also change its name to Bloomia Holdings, Inc. and trade under the new NASDAQ ticker symbol TULP.

Lendway Inc. has announced a strategic rights offering aimed at significantly reducing its debt and strengthening its balance sheet. The company plans to use the proceeds to settle a sellers’ note for a discount exceeding 50% of the outstanding balance and pay off a substantial amount of other debt. If the rights offering is successful, Lendway’s overall debt could be reduced by up to 40% immediately and potentially by as much as 70% by early summer. The company also intends to change its corporate name to Bloomia Holdings, Inc. and trade under the new NASDAQ ticker symbol TULP. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lendway Inc. published the original content used to generate this news brief on January 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [BPTH.US - Bio-Path](https://longbridge.com/en/quote/BPTH.US.md)
- [LDWY.US - Lendway](https://longbridge.com/en/quote/LDWY.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference | Alumis (NASDAQ:ALMS) executives presented Phase 3 psoriasis results for envudeucitinib at the Oppenheimer Healthcare Con | [Link](https://longbridge.com/en/news/277123919.md) |
| Forecasting The Future: 4 Analyst Projections For Arcutis Biotherapeutics | Recent analyst projections for Arcutis Biotherapeutics (NASDAQ:ARQT) show a mix of bullish and bearish sentiments. Over  | [Link](https://longbridge.com/en/news/277080798.md) |
| Cytokinetics Q4 net loss widens | Cytokinetics reported a widened net loss of $183 million for Q4, despite a year-over-year revenue increase driven by MYQ | [Link](https://longbridge.com/en/news/276786332.md) |
| BUZZ-Soleno Therapeutics shares rise on CFO appointment | Shares of Soleno Therapeuticsrose 1.19% to $41.50 in premarket trading following the appointment of Jennifer Fulk as CFO | [Link](https://longbridge.com/en/news/277047522.md) |
| BridgeBio Q4 revenue jumps on Attruby sales | BridgeBio's Q4 revenue surged, primarily due to a 35% increase in Attruby sales. The company reported positive Phase 3 t | [Link](https://longbridge.com/en/news/276786305.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.